FDA Approves HALOPERIDOL DECANOATE — Sagent Pharmaceuticals

Sagent Pharmaceuticals announced the FDA approval of Haloperidol Decanoate, enhancing domestic access to this intramuscular antipsychotic therapy. The approval is projected to provide significant market implications by addressing supply shortages for healthcare providers requiring a stable, long-acting formulation.